Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:45:48.945Z.
Calculation as of: 2026-10-06T14:45:48.945Z.
Quote observation: 2026-10-06T14:44:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1148a26bf5d8a77c385830e28adfe1a3226667ff180e3eaa52d15dba3998f7d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Bluejay Diagnostics, Inc.
Market Cap
$832945.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835190.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$869976.00
EV/EBITDA Ratio
N/A
TTM Avg
1464.50x
3Y Avg
6462.34x
5Y Avg
6462.34x
Market Cap
$870069.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$674387.00
EV/EBITDA Ratio
4.13x
TTM Avg
10.27x
3Y Avg
9.51x
5Y Avg
9.51x
Market Cap
$1.03M
EV/EBITDA Ratio
N/A
TTM Avg
1.21x
3Y Avg
1.21x
5Y Avg
1.21x
Market Cap
$1.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $832945.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $869976.00 | N/A | 1464.50x | 6462.34x | 6462.34x |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $674387.00 | 4.13x | 10.27x | 9.51x | 9.51x |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 1.21x | 1.21x | 1.21x |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $552749.00 | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
